🐻 CBRS $2.5M Tail-Hedge Put — Someone Is Betting Cerebras Could Crash Another 39%!

📅 June 25, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just paid $2.5 MILLION for a far-out-of-the-money put on Cerebras Systems — a bet (or crash insurance) that the AI chip darling could fall another ≈39% to $105 by August 21. This is the second straight session of deep-OTM put buying on CBRS: yesterday it was the August $115 strike; today the $105 strike. When the same bearish theme shows up two days in a row on a freshly-IPO'd name already sliding below its offer price, that's a persistent overhang signal worth watching closely. 👀

---

💼 Company Overview

Cerebras Systems (CBRS) is the company behind the Wafer-Scale Engine 3 (WSE-3) — described as the world's largest commercialized AI processor, roughly 58× larger than a leading GPU, delivering inference up to 15× faster at a fraction of the power per compute unit. The hardware is packaged in CS-3 systems and sold increasingly as an AI inference cloud, positioning Cerebras as a low-latency-inference challenger to NVIDIA.

• Market Cap: ≈$47–51B (≈219.6M shares outstanding)
• Sector: AI Semiconductors / AI Infrastructure
• IPO Date: May 14, 2026 — the largest semiconductor IPO ever, priced at $185, surged to a $311 first-day close (+68%)
• Current Price: ≈$173 — now below the IPO price and sliding
• Forward Revenue Multiple: ≈54–58× FY2026 guidance of $855–865M — an expensive name priced for perfect execution

Real talk: Cerebras has a genuinely differentiated product in the low-latency inference market. The question in the market right now is whether that product can generate the margins needed to justify this valuation. After last Monday's earnings, the answer scared investors.

---

💰 The Option Flow Breakdown

📊 What Just Happened

A single large order hit the tape at 09:50 ET this morning — right at the open, before the stock found any footing. Here's the full breakdown:

Flow Tag: 🔁 Single-leg auction (a facilitated price-improvement auction — a broker-routed block filled at price improvement, not a lit-book sweep)

Key numbers at a glance:

• 💸 Premium paid: $2.5M ($1.98 per contract × 12,655 contracts × 100 shares)
• 📉 Strike distance: $105 is ≈39% below the $173.18 spot price at the time of the trade
• 📅 Days to expiry: 57 days (to August 21, 2026)
• 🆕 Open Interest before the trade: 0 — this strike did not exist before today's print

---

✅ Open/Close Check — RESOLVED: Fresh OPEN Confirmed

The June 26 pre-market OPRA snapshot (reflecting June 25 end-of-day) is in, and it confirms the size-proven read: this was a fresh opening BUY (BTO) of the August 21 $105 put.

Open interest went from zero to 12,806 — slightly above the 12,655 print (other small adds at the strike), confirming the entire block as new contracts entering the market. There was nothing to close. This is about as clean a confirmed open as it gets: a brand-new far-OTM downside-protection / tail-hedge position.

---

🤓 What This Actually Means — Plain English

Let's break down what's really happening with this trade, piece by piece.

What is a $105 put on a $173 stock?

A put option gives the buyer the right to sell CBRS at $105 per share by August 21. For that to make money, CBRS would need to fall from $173 all the way down to below $105 — a drop of ≈39% in about 57 days. That's a steep hill to climb (or fall, in this case).

The $1.98 price tag per contract reflects exactly how unlikely the market thinks this is — cheap options like this are called "out-of-the-money tail risk" plays. The buyer paid about 1.1% of the stock price for protection against a scenario the market prices as a long shot.

How it was filled — single-leg auction:

The tape shows this as a single-leg auction (a facilitated price-improvement auction). This means a broker routed the order to an exchange auction process, where competing market makers bid to fill it at the best price rather than just hitting the displayed book. This is a common mechanism for large institutional blocks — it's not the same as an aggressive lit sweep where someone is urgently consuming every seller. The buyer got price improvement on a $2.5M order. We checked the equity tape and found no paired stock block — this is a pure options-only directional position, not a hedged package.

Why buy a 39%-OTM put?

Think of it like buying earthquake insurance on a new house. You hope you never need it, and the premium is cheap precisely because a 39% crash in 57 days is unlikely. But if the quake hits, the payout is enormous. A $2.5M premium on 12,655 contracts gives maximum payout at expiry of roughly $86.4M if CBRS goes to zero (12,655 × 100 × $105 intrinsic value minus the $1.98 cost). Even a slide to $130 would mean ≈$30M in profits.

Why is this a rational trade right now?

The timing is not random. Consider what CBRS faces in the next several months:

1. Margin story just broke down. Cerebras's first post-IPO earnings on June 23 showed Q1 gross margin of 47% — then guided Q2 to 36–38% gross margin, a ≈1,000 basis point collapse in one quarter. Revenue was strong (+92% YoY), but profitability fears dominate right now.

2. Q2 2026 earnings ≈September 2. The next report is the first chance to confirm whether that margin guide was a one-quarter blip or the new normal. If margins disappoint again on a ≈55× forward-sales name, the reaction could be severe.

3. ≈Mid-November 2026 founder lockup unlock. This is the big one. The 180-day IPO lockup expires ≈mid-November, freeing up billions in founder and VC shares to sell. CEO Andrew Feldman holds ≈$1.9B and CTO Sean Lie ≈$1B at the offer price. When that supply hits the market — especially with the stock already below IPO price — the pressure could be intense.

4. Customer concentration. ≈86% of FY2025 revenue came from just two UAE-linked entities; the backlog now is almost entirely the single $20B+ OpenAI contract. As one analyst put it, concentration "rotated, it didn't go away".

This is the SECOND straight day of deep-OTM put buying on CBRS. Yesterday it was the August $115 put; today it's the August $105 put. When the same playbook repeats in consecutive sessions on a fresh IPO, that's a persistent bearish or hedging theme — not a one-off accident.

Who does this trade?

It could be: (a) a large CBRS holder buying crash insurance ahead of the lockup unlock and September earnings, spending $2.5M to protect a much larger equity position; or (b) a directional bear betting the stock cracks further. The tape cannot tell us which. What the tape CAN tell us is that someone thought $2.5M was worth paying for the right to profit if CBRS falls 39%+ in under two months. On a freshly-IPO'd name already below its offer price, that's a coherent thesis, not random noise.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

CBRS has lived through a complete emotional cycle in just six weeks of trading. The stock opened its IPO at $350 and closed its first day at $311 — a spectacular debut. Then reality began setting in: by June 23 (first earnings day), the stock had already given back most of those gains, trading around $191. The earnings call on June 23 triggered a further ≈11% after-hours drop, and the slide has continued through today at ≈$173.

The YTD chart shows a classic "IPO rocket and retrace" pattern — the kind that often continues lower as the initial excitement fades and fundamentals dominate. CBRS is now below its $185 IPO price, a psychologically important level that converts many early buyers into underwater holders.

Key observation: The stock is in a clear downtrend since the IPO close. There is no established long-term support because the price history is only six weeks old.

Gamma-Based Support & Resistance

Important note: CBRS gamma is extremely thin. This is a six-week-old IPO with a very short option chain history. The gamma chart reflects a nascent options market with limited open interest across strikes. Do not rely on gamma levels here the way you would for a seasoned mega-cap. The gamma data is directionally informative but the levels are not as battle-tested as a stock like NVDA or AAPL.

That said, reading from the gex.json data, here is what the current gamma exposure shows:

🔵 Put Gamma — Potential Support Zones:

The most significant put gamma concentrations below spot are:

• $170 — the nearest material put gamma cluster (1.35 total GEX), representing dealers with put exposure that creates buying interest on dips. This is the closest floor, and CBRS is already right at it.
• $175 — similar put gamma weight (1.32 total GEX), directly above current price; a break below this zone and $170 opens the door to lower levels.
• $160 — secondary put gamma (0.79 total GEX) — the next meaningful floor if $170 cracks.
• $115 — the deepest notable put gamma level in the data (0.80 total GEX), very far from spot but worth noting given where this put trade is struck.

🟠 Call Gamma — Resistance Zones Above:

• $185 — the IPO price and the first meaningful call gamma wall (1.65 total GEX, roughly balanced between calls and puts). A recovery to $185 would be the first psychological hurdle for bulls.
• $180 — near-term resistance with 2.28 total GEX (the single largest strike in terms of combined gamma). This is currently about 4% above spot and likely the first ceiling on any bounce.
• $200 — further resistance (1.49 total GEX, call-dominated); would require a significant sentiment shift to reach.

The big picture: The gamma map for CBRS is dominated by put gamma below spot, reflecting the bearish positioning that has built up since the post-earnings slide. There is no strong call gamma "floor" being maintained by dealers; gravity is on the downside right now.

Net GEX bias: Overwhelmingly put-heavy across the near-money strikes — consistent with a market that is positioned for continued weakness, not a bounce.

Implied Move Analysis

This chart is arguably the most important piece of data for understanding today's put trade. The options market is pricing enormous uncertainty into CBRS, reflecting its brand-new IPO status and high volatility:

Translation: The options market is pricing a 35% move (up or down) for the August 21 expiration — the exact expiry of today's put trade. That means the $105 strike, while 39% below spot, is not as outlandish as it sounds. It sits near the lower tail of the August implied range (≈$112 lower bound from the opex labels). The September $102.86 lower range says a move to $105 is within one standard-deviation territory for a three-month horizon.

The weekly implied move of ±$11 (±6.4%) in a single day shows just how volatile CBRS is. That's not a stock for the faint-hearted.

Key insight on the $105 put: At ≈35% implied move for August, a $105 strike is roughly at the 1.1–1.2 standard-deviation lower tail. It's not a "lottery ticket" in the sense of a zero-probability event — it's priced as a tail scenario that the market acknowledges is possible, just unlikely. The $1.98 premium reflects that.

---

🎪 Catalysts

✅ Already Happened (Set the Stage)

• May 14, 2026 — IPO at $185: The largest semiconductor IPO ever, pricing above the expected range and surging to $311 on day one. The first-day euphoria has entirely reversed.

• June 7, 2026 — Morgan Stanley initiates: Overweight with a $250 target when the quiet period ended, calling CBRS "one of the most differentiated AI-infra names."

• June 23, 2026 — Q1 2026 Earnings (the inflection point): Revenue beat: +92% YoY to $193.4M core. But the market focused entirely on the margin guide-down: Q2 gross margin guided to 36–38% from 47% in Q1, a ≈1,000 bps drop in one quarter. Full-year operating margin guided to −28% to −32%. Shares fell ≈11% after-hours, and the slide has continued through June 25.

• Post-earnings Morgan Stanley upgrade: Morgan Stanley raised its target to $273, maintained Overweight, and explicitly told clients to buy the dip. Consensus remains Strong Buy across ≈10 analysts with an average price target of ≈$299.

• June 24, 2026 — Day 1 of deep-OTM puts: Yesterday's tape saw buying of the August $115 put in size. Today is Day 2 with the August $105 put.

🔥 Upcoming (The Catalysts This Trade Is Watching)

• ≈September 2, 2026 — Q2 2026 Earnings: The first test of whether the 36–38% gross margin guide holds, and whether the OpenAI/AWS deployment ramp is converting backlog to revenue on schedule. Q2 core revenue consensus is ≈$194M (+88% YoY). A margin miss here, or any softening of the $24.6B backlog, would accelerate the derating. Note: The August 21 put expires before this event — but the Q2 report fear is clearly part of what's building bearish sentiment now.

• ≈Mid-November 2026 — 180-Day IPO Lockup Unlock: This is the structural wildcard. The 180-day lockup from the May 14 IPO expires ≈mid-November 2026, freeing up billions in founder/VC shares. CEO Andrew Feldman holds ≈$1.9B and CTO Sean Lie ≈$1B at the offer price. With the stock already below the offer price and insiders likely anxious to diversify, this supply could weigh heavily on the stock in the weeks leading up to November — the market often sells the anticipation. The August put expires before the unlock itself, but a position that is profitable by August could represent the first leg of a hedge that gets rolled into the November window.

• OpenAI/AWS deployment ramp (ongoing): The bull thesis rests on a $20B+ OpenAI contract and a new AWS partnership converting a ≈$24.6B backlog to revenue. Any deployment milestone is a positive catalyst; any slowdown, in-housing attempt, or renegotiation by OpenAI is a major downside catalyst. Given that customer concentration "rotated, it didn't go away", this single relationship is the entire fundamental story.

---

🎲 Price Targets & Probabilities

Using the gamma levels and implied-move data as a framework, here are the key scenarios through the August 21 expiration:

📈 Bull Case (≈25% probability for August)

Target: $182–$200

The bull case requires Morgan Stanley to be right — that the post-earnings selloff is an overreaction to a temporary margin compression driven by the AI-cloud capacity ramp. If OpenAI/AWS deployment milestones get announced, sentiment could reverse sharply. The $180 gamma wall (2.28 total GEX, the heaviest strike in the chain) would be the first major resistance. A recovery above $185 (IPO price) would attract significant positive attention. Above $200, call gamma dominates and the path becomes cleaner.

Put outcome in this scenario: The $105 puts expire worthless. The $2.5M premium is lost entirely.

🎯 Base Case (≈50% probability for August)

Target: $150–$175 (continued drift lower)

The most likely scenario is that CBRS continues its post-earnings slide, lacking a clear catalyst to reverse the margin concern before August 21. With the stock in a downtrend below its IPO price, gamma showing put-heavy positioning, and no earnings report until September, the path of least resistance is lower. $160 gamma support is the next meaningful floor below today's level; below that, $150 and $140 come into view.

Put outcome in this scenario: The $105 put expires out-of-the-money but the position loses value slowly. The buyer loses most or all of the $1.98 premium.

📉 Bear Case (≈25% probability for August)

Target: below $130 — the $105 puts begin to pay

A bear scenario requires an additional catalyst: a macro shock to AI spending, a news event around OpenAI renegotiating, an early signal that Q2 margins are worse than guided, or a general AI-semiconductor derating. Given that CBRS already has no earnings until September, the trigger would need to come from outside the company or from secondary market panic. The implied move data does put $112 in the lower range for August, meaning the market already prices this scenario with non-trivial probability.

Put outcome in this scenario: At $130, the put is ≈$25 in-the-money — the $2.5M bet turns into a position worth roughly $32M. At $105, maximum intrinsic value at expiry; the $2.5M becomes roughly $133M (before commissions). These are the numbers that make a $2.5M premium rational as tail protection.

---

💡 Trading Ideas

🛡️ Conservative: Watch and Wait

For the cautious investor: Do not try to replicate this $105 put trade. Far-OTM puts decay rapidly (theta is brutal when you're 39% out of the money) and most likely expire worthless. The institutional buyer has the balance sheet to eat a $2.5M loss; retail traders usually do not.

Instead: If you're concerned about CBRS downside, the most conservative move is simply to reduce position size or wait for the post-earnings (September) dust to settle before initiating any position. Let the margin story clarify.

Risk level: Low | Skill level: Beginner-friendly

⚖️ Balanced: Defined-Risk Put Spread

For the swing trader with a bearish lean: Rather than buying a naked $105 put (cheap but very far OTM), consider a defined-risk put spread that is closer to the money.

Possible structure: Buy the August $160 put / Sell the August $145 put. This gives you bearish exposure in a range where CBRS could realistically trade ($160–$145 is within the implied move for August), with a capped max loss of the net premium paid. Much higher probability of paying off than the $105 strike.

Why this makes sense: The gamma data shows $160 as a put-gamma support level — a break below it could accelerate the selloff. The spread monetizes a move into that territory without requiring a 39% crash.

Risk level: Moderate (defined-risk) | Skill level: Intermediate

🚀 Aggressive: Rolling the Same Theme

For experienced options traders: If you believe the bearish overhang is real and will persist into September earnings, consider following the whale's lead by legging into the August chain, but at strikes closer to the money — closer to the $150–$160 area — where the probability of payoff is meaningfully higher than 39% OTM. Manage position size carefully: CBRS implied volatility is extremely high, and options premiums reflect that.

Key risk: CBRS implied volatility is elevated — you are paying for expensive optionality. If the stock stabilizes, IV could compress and hurt your position even if direction is right.

Risk level: High | Skill level: Advanced only

---

⚠️ Risk Factors — The Honest Picture

Before you do anything with this information, understand these risks:

• ⏳ Far-OTM puts almost always expire worthless. A $105 put on a $173 stock needs a 39% crash in 57 days. Historically, this happens in extreme scenarios — black swans, sudden earnings disasters, macro panics. The buyer may be wrong. The $2.5M could go to zero. Do not treat this trade as a "signal to short CBRS" without your own analysis.

• 💔 Theta decay is the enemy. Options 39% out-of-the-money with 57 days to expiry lose value every single day from time decay, even if the stock stays flat. The $1.98 premium will erode to near zero if CBRS just trades sideways.

• 🤝 Mechanism matters for interpretation. This was a single-leg auction — a facilitated, broker-routed fill, not an aggressive lit-book sweep where someone is urgently buying puts at any price. Facilitated blocks can include holders hedging, portfolio managers doing structured programs, or firms running systematic strategies. It does not prove a "bearish conviction view" the way a sequence of aggressive market orders would.

• 🐂 Analyst consensus is strongly bullish. Morgan Stanley has a $273 target (Overweight) and told clients to buy the dip. Consensus across ≈10 analysts is ≈$299. The whale may be wrong; Wall Street analysts may be right. Smart money disagrees on this name.

• 🎢 CBRS is a 6-week-old IPO with ≈6.4% daily implied move. The options chain is immature, liquidity is thinner than established names, and bid-ask spreads are wide. Retail traders face worse execution than institutional desks.

• 🔒 The August put expires BEFORE the biggest risk events. The ≈mid-November lockup unlock and September Q2 earnings are the two largest catalysts — but both fall after the August 21 expiry. The put buyer may be expressing a view on the sentiment going into those events, not the events themselves.

• 🧨 Could be a hedge, not a directional bet. A large CBRS holder might own millions of dollars in stock (possibly acquired at the IPO or before) and is paying $2.5M for protection. If the stock rallies to $250 by August, they made far more on the stock than they lost on the puts. Never confuse a hedge for a conviction short.

---

🎯 The Bottom Line

Here's the deal: Someone just paid $2.5M for the right to profit if Cerebras falls 39%+ in the next two months. That's not a small bet on a whim — it's a deliberate, structured position in a carefully chosen far-OTM strike that creates enormous convex payoff if the stock's margin story deteriorates further, the AI spending narrative softens, or a broader derating accelerates into the August expiry.

What makes this trade compelling as a signal:

• 🔁 It's the second straight session of deep-OTM put buying on CBRS (yesterday $115s, today $105s) — a persistent, not one-off, theme
• 🏭 The strike is brand new (OI was 0), meaning someone created this position intentionally at this specific level — not a pre-existing position being closed
• 📅 The timing is deliberate: 57 days out, spanning the run-up to Q2 earnings (≈September 2) and the growing anxiety around the ≈mid-November lockup overhang
• 💰 $2.5M in premium on a ≈$47B company is not a rounding error — this is a real position with real conviction

What this trade does NOT tell us:

• Whether it's a holder hedging or a directional bear — we cannot know
• Whether the buyer is right — far-OTM puts expire worthless the majority of the time
• What the buyer's cost basis in CBRS stock is (if they own any)

The three scenarios for CBRS traders:

✅ If you own CBRS stock: Consider the growing put activity as a data point alongside the already-visible margin story. The stock is below its IPO price, sliding, and facing two major catalyst windows (September earnings and November lockup). These are legitimate risks that justify reviewing your position size and downside protection strategy. You don't need to sell everything — but having a plan for $150 or $130 is not paranoia; it's prudent.

👀 If you're watching from the sidelines: The September Q2 earnings report (≈September 2) is the next major decision point. If margins stabilize or improve, the bull case (Morgan Stanley's $273) becomes credible. If margins disappoint again, the stock has significantly further to fall. Mark that date on your calendar before initiating any new position.

🐻 If you're bearish: The tape is with you today — two days of deep-OTM put buying, a stock below IPO price in a downtrend, a ≈1,000 bps margin guide-down, and a November lockup looming. But remember: 39%-OTM puts are not efficient ways to express a short view. Closer-to-the-money put spreads give you better risk/reward if you believe the downside is coming.

Mark your calendar:

• 📅 June 26 ≈06:30 ET — ✅ RESOLVED: CBRS OI on the August $105 put rose 0 → 12,806 (Δ +12,806), confirming the fresh open (BTO)
• 📅 August 21, 2026 — Expiration of today's $105 put trade
• 📅 ≈September 2, 2026 — Q2 2026 earnings (the next margin test)
• 📅 ≈Mid-November 2026 — 180-day IPO lockup unlock (the biggest structural risk)

Final thought: When someone buys two days in a row of far-OTM puts on a freshly-IPO'd name already sliding below its offer price, they're not making a casual bet. Whether they are hedging a large long or expressing outright bearish conviction, the message is the same: the near-term risk/reward on CBRS is skewed to the downside, and someone important enough to move $2.5M in one print agrees. Take that seriously, even if the specific $105 strike feels extreme. 🐻

---

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and does not constitute financial advice. The unusual options activity described here represents the actions of a single market participant whose identity, full portfolio context, and investment objectives are unknown. Far-out-of-the-money options such as the August $105 puts described above expire worthless the vast majority of the time; replicating this trade without understanding the full risk is strongly discouraged. Past unusual options activity does not predict future stock performance. Always conduct your own research and consider consulting a licensed financial advisor before making any investment decisions. CBRS is a recently-IPO'd stock with elevated volatility, wide bid-ask spreads, and a thin options market — all of which increase execution risk for retail traders.

---

Last updated: June 26, 2026 — morning OI check confirmed the August $105 put as a fresh OPEN (BTO): OI 0 → 12,806 (Δ +12,806, slightly above the 12,655 print). Size-proven open verdict holds.

---

About Cerebras Systems (CBRS): Cerebras Systems designs the Wafer-Scale Engine 3 (WSE-3), the world's largest commercialized AI processor at ≈58× the size of a leading GPU, delivering inference up to 15× faster at a fraction of the power per compute unit. The company went public on May 14, 2026 in the largest semiconductor IPO ever, priced at $185 per share. It serves the AI inference cloud market with CS-3 hardware systems and a managed cloud offering, with a ≈$24.6B backlog anchored by a >$20B OpenAI contract and an AWS partnership. Market cap: ≈$47–51B. Sector: AI Semiconductors / AI Infrastructure.